Reshma Jagsi

Nov 19, 2024 | jamanetwork.com | Kanan Shah |Fumiko Chino |Mylin A. Torres |Reshma Jagsi

Key PointsQUESTION  How does the representation of Asian American individuals in the US allopathic physician workforce vary when disaggregated by specific subgroups? FINDINGS  This cross-sectional study analyzed 94 934 medical school applicants, 39 849 matriculants, 37 579 graduates, 229 899 residents, and 297 413 faculty identifying as Asian between 2013 to 2021.

Mar 4, 2024 | onclive.com | Reshma Jagsi

Reshma Jagsi, MD, DPhil, Lawrence W. Davis Professor, chair, Department of Radiation Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses the implications of the IDEA trial (NCT02400190) for patients with breast cancer. The overarching message Jagsi wishes to convey is her immense pride in being a part of a community of researchers who have diligently prioritized centering patients' experiences.

Mar 1, 2024 | onclive.com | Reshma Jagsi

Reshma Jagsi, MD, Dphil, Lawrence W. Davis Professor, chair, Department of Radiation Oncology, Emory University School of Medicine, discusses caveats when interpreting long-term results from the IDEA trial (NCT02400190) evaluating radiotherapy omission when administering breast conserving surgery plus endocrine therapy to postmenopausal patients with breast cancer.

Feb 20, 2024 | onclive.com | Reshma Jagsi

Reshma Jagsi, MD, Dphil, Lawrence W. Davis Professor, chair, Department of Radiation Oncology, Emory University School of Medicine, discusses 5-year findings from the IDEA trial (NCT02400190) evaluating the feasibility of breast conserving surgery followed by endocrine therapy without radiotherapy in postmenopausal patients with breast cancer.

Dec 7, 2023 | usnews.com | Reshma Jagsi

By Ernie Mundell HealthDay ReporterTHURSDAY, Dec. 7, 2023 (HealthDay News) -- Women in the their 50s and 60s who've gone through menopause may be able to safely skip radiation treatment if they're diagnosed with a common form of breast cancer, new research shows. The study focused on early stage HR+ breast cancers, which comprise the large majority of new cases. In HR+ breast cancer, tumor cells carry receptors for the hormones estrogen or progesterone.